Summary & Overview
CPT 88237: Cell Culture for Bone Marrow or Blood in Neoplastic Disorder
CPT code 88237 represents a laboratory service where cells from bone marrow or peripheral blood are cultured to evaluate neoplastic (cancerous) disorders. This code covers specialized cell-culture techniques used in the diagnosis and monitoring of hematologic malignancies and related cytogenetic investigations. The procedure is clinically important because cultured cells can reveal chromosomal abnormalities and morphological features that guide diagnosis, prognosis, and treatment planning across the United States.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of this code, typical sites of service, and common billing considerations. The publication summarizes benchmarking context, payer coverage patterns, and recent policy updates affecting laboratory and cytogenetic services. It also outlines the clinical context in which the service is used and highlights areas where coding clarity and documentation are important.
This national-level summary is intended for billing professionals, laboratory administrators, and policy analysts seeking an authoritative reference on CPT code 88237, its clinical role in neoplastic disorder evaluation, and the payer landscape relevant to laboratory diagnostic services.
Billing Code Overview
CPT code 88237 describes a laboratory procedure in which a lab analyst cultures cells from bone marrow or blood to diagnose or evaluate a neoplastic disorder. This service involves growing and observing cellular cultures to identify malignant cells, cytogenetic abnormalities, or other features relevant to hematologic malignancies.
-
Service type: Cell culture and laboratory diagnostic testing for neoplastic hematologic disorders
-
Typical site of service: Clinical laboratory or hospital laboratory setting
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient with newly diagnosed acute myeloid leukemia is referred for diagnostic workup. Peripheral blood smear shows circulating blasts and a bone marrow aspiration is performed by a hematology/oncology specialist. A specimen of bone marrow and a concurrent peripheral blood sample are sent to the clinical laboratory. The laboratory analyst performs a cell culture procedure to grow hematopoietic or neoplastic cells from the bone marrow and/or blood sample to support cytogenetic analysis, flow cytometry panels, and molecular testing for clonal populations.
The clinical workflow: the clinic collects the specimen and submits it with the requisition indicating the suspected neoplastic disorder. The laboratory receives the specimen, documents accessioning, prepares culture media, inoculates specimens into appropriate culture systems, incubates under controlled conditions, monitors growth, and harvests cells at the specified time points for downstream testing (karyotype, FISH, molecular assays). Results are reported back to the ordering hematologist/oncologist to inform diagnosis, prognostic stratification, and treatment planning.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | Use when billing only the professional interpretation component by a physician or qualified professional. |